L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 5.86 NOK 0.34% Market Closed
Market Cap: 300.5m NOK
Have any thoughts about
Lytix Biopharma AS?
Write Note

Lytix Biopharma AS
Investor Relations

Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.

Show more

Earnings Calls

Show Transcript
Previous
Next
Loading

Management

Dr. Oystein Rekdal Ph.D.
Co-Founder & CEO
No Bio Available
Mr. Gjest Breistein M.Sc.
Chief Financial Officer
No Bio Available

Contacts

Address
OSLO
Oslo
Hoffsveien 4
Contacts